BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25638158)

  • 1. Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target.
    Weingart MF; Roth JJ; Hutt-Cabezas M; Busse TM; Kaur H; Price A; Maynard R; Rubens J; Taylor I; Mao XG; Xu J; Kuwahara Y; Allen SJ; Erdreich-Epstein A; Weissman BE; Orr BA; Eberhart CG; Biegel JA; Raabe EH
    Oncotarget; 2015 Feb; 6(5):3165-77. PubMed ID: 25638158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK Inhibition Suppresses Growth of Atypical Teratoid/Rhabdoid Tumors.
    Shahab S; Rubens J; Kaur H; Sweeney H; Eberhart CG; Raabe EH
    J Neuropathol Exp Neurol; 2020 Jul; 79(7):746-753. PubMed ID: 32472116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity.
    Rubens JA; Wang SZ; Price A; Weingart MF; Allen SJ; Orr BA; Eberhart CG; Raabe EH
    Neuro Oncol; 2017 Oct; 19(10):1361-1371. PubMed ID: 28582547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.
    Hashizume R; Zhang A; Mueller S; Prados MD; Lulla RR; Goldman S; Saratsis AM; Mazar AP; Stegh AH; Cheng SY; Horbinski C; Haas-Kogan DA; Sarkaria JN; Waldman T; James CD
    Neuro Oncol; 2016 Nov; 18(11):1519-1528. PubMed ID: 27370397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors.
    Meel MH; Guillén Navarro M; de Gooijer MC; Metselaar DS; Waranecki P; Breur M; Lagerweij T; Wedekind LE; Koster J; van de Wetering MD; Schouten-van Meeteren N; Aronica E; van Tellingen O; Bugiani M; Phoenix TN; Kaspers GJL; Hulleman E
    Neuro Oncol; 2020 Jan; 22(1):58-69. PubMed ID: 31504799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent overexpression of HMGA2 in human atypical teratoid/rhabdoid tumor and its correlation with let-7a3/let-7b miRNA.
    Zhang K; Gao H; Wu X; Wang J; Zhou W; Sun G; Wang J; Wang Y; Mu B; Kim C; Chu P; Ho DM; Ann DK; Wong TT; Yen Y
    Clin Cancer Res; 2014 Mar; 20(5):1179-89. PubMed ID: 24423609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Targeting of PTK7 is Cytotoxic in Atypical Teratoid Rhabdoid Tumors.
    Messerli SM; Hoffman MM; Gnimpieba EZ; Bhardwaj RD
    Mol Cancer Res; 2017 Aug; 15(8):973-983. PubMed ID: 28442586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo.
    Alimova I; Pierce A; Danis E; Donson A; Birks DK; Griesinger A; Foreman NK; Santi M; Soucek L; Venkataraman S; Vibhakar R
    Int J Cancer; 2019 Apr; 144(8):1983-1995. PubMed ID: 30230537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid/rhabdoid tumors.
    Choi SA; Choi JW; Wang KC; Phi JH; Lee JY; Park KD; Eum D; Park SH; Kim IH; Kim SK
    Neuro Oncol; 2015 Jun; 17(6):810-21. PubMed ID: 25378634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SMARCB1 Gene Therapy Using a Novel Tumor-Targeted Nanomedicine Enhances Anti-Cancer Efficacy in a Mouse Model of Atypical Teratoid Rhabdoid Tumors.
    Kim SS; Moghe M; Rait A; Donaldson K; Harford JB; Chang EH
    Int J Nanomedicine; 2024; 19():5973-5993. PubMed ID: 38895149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.
    Lee S; Cimica V; Ramachandra N; Zagzag D; Kalpana GV
    Cancer Res; 2011 May; 71(9):3225-35. PubMed ID: 21521802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program.
    Mao XG; Hütt-Cabezas M; Orr BA; Weingart M; Taylor I; Rajan AK; Odia Y; Kahlert U; Maciaczyk J; Nikkhah G; Eberhart CG; Raabe EH
    Oncotarget; 2013 Jul; 4(7):1050-64. PubMed ID: 23846349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of a mouse model of atypical teratoid/rhabdoid tumor of the central nervous system through combined deletion of Snf5 and p53.
    Ng JM; Martinez D; Marsh ED; Zhang Z; Rappaport E; Santi M; Curran T
    Cancer Res; 2015 Nov; 75(21):4629-39. PubMed ID: 26363008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Lin28A/let-7a/c-Myc Pathway in Growth and Malignant Behavior of Papillary Thyroid Carcinoma.
    Huang J; Lin H; Zhong M; Huang J; Sun S; Lin L; Chen Y
    Med Sci Monit; 2018 Dec; 24():8899-8909. PubMed ID: 30531691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional relevance of genes predicted to be affected by epigenetic alterations in atypical teratoid/rhabdoid tumors.
    Tegeder I; Thiel K; Erkek S; Johann PD; Berlandi J; Thatikonda V; Frühwald MC; Kool M; Jeibmann A; Hasselblatt M
    J Neurooncol; 2019 Jan; 141(1):43-55. PubMed ID: 30446899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rhabdoid tumor growth is inhibited by flavopiridol.
    Smith ME; Cimica V; Chinni S; Challagulla K; Mani S; Kalpana GV
    Clin Cancer Res; 2008 Jan; 14(2):523-32. PubMed ID: 18223228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis.
    Darr J; Klochendler A; Isaac S; Eden A
    Oncogene; 2014 Jun; 33(23):3024-32. PubMed ID: 23851500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repositioning disulfiram as a radiosensitizer against atypical teratoid/rhabdoid tumor.
    Lee YE; Choi SA; Kwack PA; Kim HJ; Kim IH; Wang KC; Phi JH; Lee JY; Chong S; Park SH; Park KD; Hwang DW; Joo KM; Kim SK
    Neuro Oncol; 2017 Aug; 19(8):1079-1087. PubMed ID: 28340172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The chromatin-modifying protein HMGA2 promotes atypical teratoid/rhabdoid cell tumorigenicity.
    Kaur H; Hütt-Cabezas M; Weingart MF; Xu J; Kuwahara Y; Erdreich-Epstein A; Weissman BE; Eberhart CG; Raabe EH
    J Neuropathol Exp Neurol; 2015 Feb; 74(2):177-85. PubMed ID: 25575139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SMAD dependent signaling plays a detrimental role in a fly model of SMARCB1-deficiency and the biology of atypical teratoid/rhabdoid tumors.
    Jeibmann A; Schulz J; Eikmeier K; Johann PD; Thiel K; Tegeder I; Ambrée O; Frühwald MC; Pfister SM; Kool M; Paulus W; Hasselblatt M
    J Neurooncol; 2017 Feb; 131(3):477-484. PubMed ID: 28108836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.